Schimmel KJ - Search Results

1

Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.

Schimmel KJ, Nijmeijer BA, van Schie ML, Falkenburg JH, Guchelaar HJ. Schimmel KJ, et al. Leuk Res. 2007 Nov;31(11):1545-51. doi: 10.1016/j.leukres.2007.03.022. Epub 2007 Apr 24. Leuk Res. 2007. PMID: 17459472

2

Cardiotoxicity of cytotoxic drugs.

Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Schimmel KJ, et al. Cancer Treat Rev. 2004 Apr;30(2):181-91. doi: 10.1016/j.ctrv.2003.07.003. Cancer Treat Rev. 2004. PMID: 15023436 Review.

3

Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats.

Schimmel K, Bennink R, de Bruin K, Leen R, Sand K, van den Hoff M, van Kuilenburg A, Vanderheyden JL, Steinmetz N, Pfaffendorf M, Verschuur A, Guchelaar HJ. Schimmel K, et al. Arch Toxicol. 2005 May;79(5):268-76. doi: 10.1007/s00204-004-0633-5. Epub 2005 Feb 2. Arch Toxicol. 2005. PMID: 15902424

4

Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine.

Schimmel K, Guchelaar HJ, van Kan E. Schimmel K, et al. Drug Dev Ind Pharm. 2006 Apr;32(4):497-503. doi: 10.1080/03639040500529150. Drug Dev Ind Pharm. 2006. PMID: 16638688

5

Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.

Schimmel KJ, Gelderblom H, Guchelaar HJ. Schimmel KJ, et al. Curr Cancer Drug Targets. 2007 Aug;7(5):504-9. doi: 10.2174/156800907781386579. Curr Cancer Drug Targets. 2007. PMID: 17691910 Review.

6

Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry.

Schimmel K, van Lenthe H, Leen R, Kulik W, Verschuur A, Guchelaar HJ, van Kuilenburg A. Schimmel K, et al. Biomed Chromatogr. 2008 Dec;22(12):1368-73. doi: 10.1002/bmc.1067. Biomed Chromatogr. 2008. PMID: 18661479

7

Pharmacogenetics of taste: turning bitter pills sweet?

Nagtegaal MJ, Swen JJ, Hanff LM, Schimmel KJ, Guchelaar HJ. Nagtegaal MJ, et al. Among authors: schimmel kj. Pharmacogenomics. 2014 Jan;15(1):111-9. doi: 10.2217/pgs.13.229. Pharmacogenomics. 2014. PMID: 24329195 Review.

8

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.

Ketzer S, Schimmel K, Koopman M, Guchelaar HJ. Ketzer S, et al. Clin Pharmacokinet. 2018 Apr;57(4):455-473. doi: 10.1007/s40262-017-0590-9. Clin Pharmacokinet. 2018. PMID: 28853050 Free PMC article. Review.

9

Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.

de Wilde S, de Jong MGH, Le Brun PPH, Guchelaar HJ, Schimmel KJM. de Wilde S, et al. Among authors: schimmel kjm. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):3-8. doi: 10.1002/pds.4335. Epub 2017 Oct 19. Pharmacoepidemiol Drug Saf. 2018. PMID: 29047193 Review.

10

The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome.

de Wilde S, de Jong MGH, Lipka AF, Guchelaar HJ, Schimmel KJM. de Wilde S, et al. Among authors: schimmel kjm. Eur J Pharm Sci. 2018 Mar 1;114:24-29. doi: 10.1016/j.ejps.2017.11.025. Epub 2017 Nov 28. Eur J Pharm Sci. 2018. PMID: 29191521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters